Wanbury Ltd(WANBURY)

NSE: WANBURYBSE: 524212

₹ 178-4.40%refreshed 23 Oct, 03:30 pm ISTMarket cap: ₹ 622 crWebsite: www.wanbury.comUpdated: 24 Oct 2026

About

Wanbury Ltd makes active pharmaceutical ingredients (APIs) and also runs a domestic formulations business in India. It is India's largest manufacturer of Metformin HCl and the largest exporter of Sertraline HCl to the EU and US, with about 10% and about 30% global market share in these two molecules. Reported FY26 revenue was 650.27, with API revenue of ₹574 cr, 88% of sales.^[1][2][3]

Business segments

API: FY26 revenue ₹574 cr, up 8%, making up 88% of sales; about 80% of it exported to the EU, Brazil and the US.^[3][1]
Domestic formulations: FY26 sales Rs. 76.93 Crore, against Rs.66.28 Crore in FY25; the business reached financial break-even in FY26.^[1][4][3]
Formulations revenue fell 12% YoY in Q4 FY26.^[3]

Products and brands

Commercial APIs as of FY26: Metformin HCl, Sertraline HCl, Tramadol HCl, Mefenamic Acid, Metformin HCl DC, Diphenhydramine Citrate, Paroxetine, Diphenhydramine HCl and an Anaesthetic API.^[1]
APIs due for commercialisation soon: Quetiapine Fumarate, Dextromethorphan HBr, Rivaroxaban and Imeglimin HCl.^[1]
The first commercial shipment of the new high-demand Anaesthetic API was made on 30 January 2026, to a European customer.^[1][5]
C-RED, a liposomal iron formulation for anaemia, was launched regionally in North and South India, with a pan-India roll-out planned.^[1]
Coriminic CPM Drops and Coriminic NS Nasal Drops target India's approximately Rs. 80 crore Cold Preparation Liquid market.^[1]

Manufacturing and approvals

Two API sites, Tanuku (Andhra Pradesh) and Patalganga (Maharashtra), with combined installed reactor capacity of about 500 KL and room for about 100 KL more brownfield capacity (FY26).^[1]
Both sites are USFDA approved; the 2025 USFDA inspection at Patalganga ended with zero 483 observations.^[1][6]
Patalganga cleared South Korea's MFDS inspection with zero observations in April 2026.^[1]
Tanuku completed an Australian TGA inspection; once the GMP certificate is received, Wanbury can ship 3 more APIs.^[1]
ANVISA approved Sertraline Form II, adding to the existing Form I approval; the company also received WHO GMP approval from CDSCO.^[1]
Debottlenecking over the last 3 years raised Metformin capacity by 25% and Sertraline capacity by 20%, per the Q4 FY26 call.^[3]

Key operating numbers

DMF/CEP filings: 70 in total, of which 64 approved and 6 pending, as of Q2 FY26.^[6][5]
Gross margin was 57.6% in FY26, up 616 bps, helped by better yields, solvent recovery and cheaper procurement.^[3]
Borrowing cost fell from about 21% to 12.5% from 1 March 2025 after refinancing.^[1]
Over 1200 employees as of FY26.^[1]

Customers and markets

APIs are exported to more than 50 countries; the main markets are the US, the EU, Brazil, South Korea and Australia (FY26).^[1]
Exports were 80% of sales in FY26.^[3]
Wanbury holds a 75% market share for sertraline in Brazil (FY26).^[1]
The West Asia crisis hit API export dispatches in March 2026; Q4 FY26 revenue was ₹164.6 cr, down 4% YoY.^[3]

Expansion and pipeline

FY27 API capex of ₹63 cr is planned for a new production block, clean rooms and debottlenecking; FY26 API capex was planned at ₹64 cr.^[5][6]
Plan to commercialise about 4 new API molecules each year from FY27.^[1][3]
Reactor capacity at existing sites could be expanded to 600 KL, using brownfield land at Tanuku.^[3]
A 1.5 MW solar project at Satara is planned to meet 70% of the Patalganga site's energy needs.^[3]
Formulations plans to shift towards cardiology, diabetes, paediatrics and dermatology.^[3]

Recent developments

8 Oct 2026: filed a new DMF in South Africa for Tramadol HCl API, plus DMFs in the Philippines and Singapore for Metformin HCl API.^[7]
12 Oct 2026: Wanbury Skin Health Limited launched the berrysoft baby product range across several Indian states, entering paediatric dermatology.^[8]
SAP S/4HANA ERP went live on October 3, 2025, with Deloitte as implementation partner.^[1]

Market Cap

₹622 Cr

High / Low

₹360 / 162

Stock P/E

25.1

Price / Book

13.0

Book Value

₹41

EPS

₹18.9

No. of Shares

3.49 Cr

ROCE

31.3%

ROE

64.9%

OPM

14.3%

Debt / Equity

1.49

Sales

₹650 Cr

Net Profit

₹66 Cr

Promoter holding

43.0%

Loading chart…

Signal history

AI Deep Dive

The analysis Screener can't give you

Our models read the latest earnings call, annual report, and financials end-to-end - then grade management, value the business, and flag the risks. Unlock all of it for this company:

Verdict
The headline call - descriptive label, conviction, and the synthesis behind it.
Valuation
Guidance-anchored P&L bridge - worst / average / best multiple cases.
Walk the talk
Did management deliver on past guidance? A commitment-by-commitment scorecard.
Red flags
Forensic and governance risk pointers, severity-ranked.
Balance sheet
Solvency and earnings-quality score.
Concall briefs
Quarter-by-quarter earnings-call briefs - what changed and why.

₹49 unlocks this company for 90 days, ₹299 for a full year - bundles bring it lower. Built on public disclosures - educational, not investment advice.

AI Deep Dive

Verdict

Locked

The headline call - descriptive label, conviction, and the synthesis behind it.

Company data

Financials